Search Immortality Topics:

Page 11234..1020..»


Pharmacogenomic studyA pilot study of the effect of pharmacogenomic phenotypes on the adequate dosing of … – Nature.com

Posted: April 9, 2024 at 1:05 pm

Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache. 2021;61:608.

Article PubMed Google Scholar

Collaborators. GDaIIaP. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 19902015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545602.

Article Google Scholar

Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, burden, and comorbidity. Neurol Clin. 2019;37:63149.

Article PubMed Google Scholar

Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53:64455.

Article PubMed Google Scholar

Matharu MS, Boes CJ, Goadsby PJ. Management of trigeminal autonomic cephalgias and hemicrania continua. Drugs. 2003;63:163777.

Article CAS PubMed Google Scholar

Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ. Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines. Headache. 2016;56:1093106.

Article PubMed Google Scholar

Burch R. Preventive migraine treatment. Continuum. 2021;27:61332.

PubMed Google Scholar

Wu JW, Yang CP. 2022 Taiwan Guidelines for Preventive Treatment of Migraine. Acta Neurol Taiwan. 2022;31:164202.

Google Scholar

Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of. Neurol Am Headache Soc Neurol 2012;78:133745.

CAS Google Scholar

Kowalska M, Prendecki M, Piekut T, Kozubski W, Dorszewska J. Migraine: Calcium Channels and Glia. Int J Mol Sci. 2021;22:2688.

Di Stefano V, Rispoli MG, Pellegrino N, Graziosi A, Rotondo E, Napoli C, et al. Diagnostic and therapeutic aspects of hemiplegic migraine. J Neurol Neurosurg Psychiatry. 2020;91:76471.

Article PubMed Google Scholar

Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. JAMA. 1983;250:25002.

Article CAS PubMed Google Scholar

Yu W, Horowitz SH. Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil. Neurology. 2003;60:1201.

Article PubMed Google Scholar

Petersen AS, Barloese MCJ, Snoer A, Soerensen AMS, Jensen RH. Verapamil and cluster headache: still a mystery. a narrative review of efficacy, mechanisms and perspectives. Headache. 2019;59:1198211.

Article PubMed Google Scholar

Gabai IJ, Spierings EL. Prophylactic treatment of cluster headache with verapamil. Headache. 1989;29:1678.

Article CAS PubMed Google Scholar

Jnsdttir M, Meyer JS, Rogers RL. Efficacy, side effects and tolerance compared during headache treatment with three different calcium blockers. Headache. 1987;27:3649.

Article PubMed Google Scholar

Fotuhi M, Glaun B, Quan SY, Sofare T. Vestibular migraine: a critical review of treatment trials. J Neurol. 2009;256:7116.

Article PubMed Google Scholar

Pomes LM, Guglielmetti M, Bertamino E, Simmaco M, Borro M, Martelletti P. Optimising migraine treatment: from drug-drug interactions to personalized medicine. J Headache Pain. 2019;20:56.

Article PubMed PubMed Central Google Scholar

Cutrer FM, Moyer AM, Atkinson EJ, Wang L, Tian S, Wu Y, et al. Genetic variants related to successful migraine prophylaxis with verapamil. Mol Genet Genomic Med. 2021;9:e1680.

Busse D, Cosme J, Beaune P, Kroemer HK, Eichelbaum M. Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharm. 1995;353:11621.

Article CAS Google Scholar

Jin Y, Wang YH, Miao J, Li L, Kovacs RJ, Marunde R, et al. Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. Clin Pharm Ther. 2007;82:57985.

Article CAS Google Scholar

Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, Eichelbaum M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharm. 1993;348:3327.

Article CAS Google Scholar

Tracy TS, Korzekwa KR, Gonzalez FJ, Wainer IW. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharm. 1999;47:54552.

Article CAS Google Scholar

Zhao LM, He XJ, Qiu F, Sun YX, Li-Ling J. Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. Br J Clin Pharm. 2009;68:395401.

Article CAS Google Scholar

Borlak J, Walles M, Levsen K, Thum T. Verapamil: metabolism in cultures of primary human coronary arterial endothelial cells. Drug Metab Dispos. 2003;31:88891.

Article CAS PubMed Google Scholar

Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of Cytochrome P450 Alleles: A meta-analysis of population-scale sequencing projects. Clin Pharm Ther. 2017;102:688700.

Article CAS Google Scholar

Amitriptyline [package insert]. Prinston, NJ: Sandoz Inc.; 2014.

PAMELOR (nortriptyline) [package insert]. Hazelwood, MO: Mallinckrodt Pharmaceuticals; 2019.

EFFEXOR XR (venlafaxine) [package insert]. Philadelphia, PA: Pfizer; 2021.

Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Mller DJ, Shimoda K, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharm Ther. 2017;102:3744.

Article CAS Google Scholar

Jiang F, Kim HD, Na HS, Lee SY, Seo DW, Choi JY, et al. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes. Psychopharmacology. 2015;232:1899909.

Article CAS PubMed Google Scholar

The Royal Dutch Pharmacists Association-Pharmacogenetics Working Group (DPWG). Dutch guidelines August 2019 update.

CALAN SR (verapamil) [package insert]. New York, NY: Pfizer; 2019.

Fuhr U, Mller-Peltzer H, Kern R, Lopez-Rojas P, Jnemann M, Harder S, et al. Effects of grapefruit juice and smoking on verapamil concentrations in steady state. Eur J Clin Pharm. 2002;58:4553.

Article CAS Google Scholar

Benowitz NL, Peng M, Jacob P 3rd. Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. Clin Pharm Ther. 2003;74:46874.

Article CAS Google Scholar

Bauer M, Karch R, Zeitlinger M, Philippe C, Rmermann K, Stanek J, et al. Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[11C]verapamil PET study. J Cereb Blood Flow Metab. 2015;35:7436.

Article CAS PubMed PubMed Central Google Scholar

Eriksen MK, Thomsen LL, Olesen J. Sensitivity and specificity of the new international diagnostic criteria for migraine with aura. J Neurol Neurosurg Psychiatry. 2005;76:2127.

Article CAS PubMed PubMed Central Google Scholar

Kelman L. The aura: a tertiary care study of 952 migraine patients. Cephalalgia. 2004;24:72834.

Article CAS PubMed Google Scholar

Read the rest here:
Pharmacogenomic studyA pilot study of the effect of pharmacogenomic phenotypes on the adequate dosing of ... - Nature.com

Recommendation and review posted by G. Smith

VA Pharmacogenomics Program Offers Opportunity For Safer, More Effective Medication Therapy – Veterans Affairs

Posted: April 9, 2024 at 1:05 pm

The Cincinnati VA Medical Center (CVAMC) now offers Pharmacogenomic (PGx) testing for Veterans enrolled in VA health care.

The pharmacogenomics testing for veterans (PHASER) program gives you the opportunity to work with VA providers on determining which medications are most effective for you based on your genetics, and it only requires one blood test.

What is the PHASER program and how does it benefit me?

The PHASER program supports free PGx testing for Veterans. PGx testing under the PHASER program can help reduce medication trial and error and hospitalizations caused by adverse reactions to medicines. The PHASER program can be utilized within multiple areas of care, including mental health, pain management, infectious disease, oncology, cardiology, gastroenterology, transplant specialty (immunology), and more with continuous expansion into other specialties and medications.

What is Pharmacogenomics (PGx) and how do I pronounce it?

Pharmacogenomics (PGx), pronounced far-ma-CO-gen-o-MIX, uses information from genes to assist in understanding how a person responds to medicines. Genes are part of DNA that provides instructions on how the body develops and functions. Because people have differences in their genes, they may respond to medicines differently.

What is PGx testing?

PGx testing is a type of genetic testing that focuses on how your body processes or responds to medicines. Along with other medical information, PGx test results help providers determine if there is a better type of medication or dose for an individual.

Will PGx testing inform me of my risk for any diseases?

The PGx test may identify an increased risk for certain, uncommon, health conditions that were passed down to you from your parents. In this case, you and your provider will be informed, and your provider will talk to you about what (if any) next steps are recommended.

What are the limitations of PGx testing?

Genetics illuminates only part of a persons story. Other considerations like age, overall health, other medicines, and body size also play a role in how you respond to medication.

Is there harm associated with PGx testing?

A blood draw is all you need to have PGx testing done. Like other tests that require blood draws, PGx testings risk is low.

Is PGx testing available to me?[BSJV1]

Currently, Veterans who receive health care at Cincinnati VAMC and other participating VA facilities, can get PGx testing done. Talk to your VA provider(s) about PGx testing. They will explain the test, answer any questions you or your caregiver have, and if you are interested in moving forward, your provider will order the test for you.

How do I get the test done?

PGx testing requires a blood draw, which you can get done at the VA.

How long does it take to receive my results?

It may take up to 2 weeks for results to be available for you and your provider. You will receive an easy to read report that you can discuss with your provider(s) to see if changes are necessary. Do not change any medications prior to talking to your provider(s).

Next steps

Veterans interested in the PHASER program should contact their primary care provider to discuss PGx testing.

For more information about the PHASER program and PGx testing, click here.

Here is the original post:
VA Pharmacogenomics Program Offers Opportunity For Safer, More Effective Medication Therapy - Veterans Affairs

Recommendation and review posted by G. Smith

Hackensack Meridian Neuroscience Institute at JFK University Medical Center Receives $2.2 Million Research Grant to … – Newswise

Posted: April 9, 2024 at 1:04 pm

Hackensack Meridian Neuroscience Institute at JFK University Medical Center announced today that it has been awarded a major research grant from the National Institute of Neurological Disorders and Stroke, part of the U.S. National Institutes of Health, to study a novel approach on whether the blocking of formation of Neutrophil extracellular traps (NET) provides better outcomes after a Traumatic Brain Injury (TBI). The five-year award of $2,213,750 is part of the highly competitive NIH extramural grant application process that recognizes innovative scientific projects. NIH-funded research has led to scientific breakthroughs and new treatments that help people live longer, healthier lives.

The NIH grant will fund a project entitled Neutrophil Extracellular Traps And Associated Pathogenesis In TBI: A Novel Peptide Therapeutic Strategy proposed by Mohammed Abdul Muneer, MSc, PhD, Research Scientist & Principal Investigator, Hackensack Meridian Neuroscience Institute at JFK University Medical Center, and Associate Professor of Neurology at the Hackensack Meridian School of Medicine.

The work hypothesizes that inhibition of peptidyl arginine deiminase type 4 (PAD4), an enzyme required for NET formation, using PAD4 antagonistic peptide (PAP), will attenuate the formation of NET, NET-induced thrombosis, and will promote neovascularization and functional recovery after TBI.

We are honored to receive this prestigious NIH grant, said Gregory J. Przybylski, M.D., MBA, chairman, Hackensack Meridian Neuroscience Institute at JFK University Medical Center, and Professor of Neurosurgery at the Hackensack Meridian School of Medicine. I congratulate Dr. Muneer and his team for this incredible achievement. This is yet another research grant that he has received from the NIH. It is a testament to his hard work, dedication, and leadership in the neuroscience field.

The Muneer lab at the Hackensack Meridian Neuroscience Institute at JFK University Medical Center seeks to demonstrate a unique therapeutic strategy for TBI focusing on the activation of leukocytes, especially neutrophils that cause the release of nuclear and granular contents to form an extensive web-like structure of DNA called neutrophil extracellular traps (NET). In TBI, the mechanism of injury-induced formation of NET and its mechanistic regulatory role in thrombosis have remained elusive. Moreover, it is unclear whether blocking NET formation provides better outcomes after TBI. Therefore, Dr. Muneers novel research efforts to suppress the formation of NET will provide critical information potentially supporting a valuable new therapeutic strategy to enhance functional recovery following TBI.

My research team and I will study an approach to suppressing the formation of NET, which may be a valuable therapeutic strategy, and analyze the efficacy of the therapy in the functional recovery level after TBI, said Dr. Muneer.

The Neuroscience Institute at JFK University Medical Center has been in existence for over 30 years, said Gay Holstein, PhD, translation research, Neuroscience Institute at JFK University Medical Center. We are honored to receive this research grant and look forward to the findings.

TBI is such an omnipresent problem, its critical to have our talented researchers findings new ways to improve and lengthen lives for this significant patient population, said Ihor Sawczuk, M.D., FACS, president of Academics, Research, and Innovation at Hackensack MeridianHealth, founding chair of the Hackensack MeridianHealthResearch Institute, and associate dean of Clinical Integration and professor and chair emeritus of Urology at the Hackensack Meridian School of Medicine.

Link:
Hackensack Meridian Neuroscience Institute at JFK University Medical Center Receives $2.2 Million Research Grant to ... - Newswise

Recommendation and review posted by G. Smith

French sales subsidiary of Japanese pharma firm Eisai divests rights of neurology drugs for 56.5 M – BSA bureau

Posted: April 9, 2024 at 1:04 pm

Japan headquartered pharma company Eisai Co. has announced that its French sales subsidiary Eisai S.A.S. has entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the Territory for the antipsychotic, Loxapac (generic name: loxapine) and the Parkinson's disease treatment ParkinaneLP (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics, based in UK.

Following the signature of this agreement, a transition period had opened during which the required implementation steps will be carried out in order for CNX to become able to operate directly the business, including the regulatory steps for the transfer of the relevant marketing authorisations andexploitantstatus.

Under the terms of the agreement, Eisai S.A.S. will receive 56.5 million euro as a lump-sum contract payment upon completing the transaction. Eisai anticipates no changes to its consolidated financial forecast for the period ending March 31, 2024.

Eisai S.A.S. acquired the rights to both treatments in the Territory in July 2002 and has been marketing them since. With the conclusion of this agreement, Eisai believes that the value of both treatments in the Territory will be maximised based on CNXs ongoing commitment serving patients in to the fields of psychiatry and neurology.

Here is the original post:
French sales subsidiary of Japanese pharma firm Eisai divests rights of neurology drugs for 56.5 M - BSA bureau

Recommendation and review posted by G. Smith

Support for network theories of schizophrenia – Nature.com

Posted: April 9, 2024 at 1:04 pm

Hoff, P. Eugen Bleulers concept of schizophrenia and its relevance to present-day psychiatry. Neuropsychobiology 66, 613 (2012).

Article PubMed Google Scholar

Di Biase, M. A. et al. Cell type-specific manifestations of cortical thickness heterogeneity in schizophrenia. Mol. Psychiatry 27, 20522060 (2022).

Article PubMed PubMed Central Google Scholar

Gaser, C., Nenadic, I., Buchsbaum, B. R., Hazlett, E. A. & Buchsbaum, M. S. Ventricular enlargement in schizophrenia related to volume reduction of the thalamus, striatum, and superior temporal cortex. Am. J. Psychiatry 161, 154156 (2004).

Article PubMed Google Scholar

Georgiadis, F. et al. Connectome architecture shapes large-scale cortical alterations in schizophrenia: a worldwide ENIGMA study. Mol. Psychiatry https://doi.org/10.1038/s41380-024-02442-7 (2024).

Article PubMed Google Scholar

van den Heuvel, M. P. & Sporns, O. Network hubs in the human brain. Trends Cogn. Sci. 17, 683696 (2013).

Article PubMed Google Scholar

Shafiei, G. et al. Spatial patterning of tissue volume loss in schizophrenia reflects brain network architecture. Biol. Psychiatry 87, 727735 (2020).

Article CAS PubMed Google Scholar

van Erp, T. G., Walton, E., Hibar, D. & Richter, A. Cortical abnormalities in 4474 individuals with schizophrenia and 5098 controls via the ENIGMA consortium. Biol. Psychiatry 84, 644654 (2018).

Article PubMed PubMed Central Google Scholar

Bullmore, E. T., Frangou, S. & Murray, R. M. The dysplastic net hypothesis: an integration of developmental and dysconnectivity theories of schizophrenia. Schizophr. Res. 28, 143156 (1997).

Article CAS PubMed Google Scholar

Berdenis van Berlekom, A. et al. Synapse pathology in schizophrenia: a meta-analysis of postsynaptic elements in postmortem brain studies. Schizophr. Bull. 46, 374386 (2020).

PubMed Google Scholar

Menon, V. Large-scale brain networks and psychopathology: a unifying triple network model. Trends Cogn. Sci. 15, 483506 (2011).

Article PubMed Google Scholar

Read the rest here:
Support for network theories of schizophrenia - Nature.com

Recommendation and review posted by G. Smith

SK Life Science Announces Data Presentations for XCOPRI (cenobamate tablets) CV at the 2024 American Academy … – InvestorsObserver

Posted: April 9, 2024 at 1:04 pm

PARAMUS, N.J. , April 9, 2024 /PRNewswire/ -- SK Life Science, Inc. , a U.S. pharmaceutical company in pursuit of developing treatments that will change the future of central nervous system (CNS) disorders, today announced the schedule for two oral and six poster presentations at the American Academy of Neurology (AAN) Annual Meeting taking place April 1318, 2024, virtually and in-person in Denver, Colorado . The data includes a study examining the relative bioavailability of cenobamate as an intact or crushed tablet administered either orally or via nasogastric tube, and a retrospective claims-based analysis comparing the effectiveness of cenobamate in reducing hospitalizations among patients with focal-onset seizures.

"We are looking forward to sharing data on the use and administration of XCOPRI in adults with partial-onset (focal) seizures at this year's AAN meeting," said Louis Ferrari , RPh, MBA, vice president, Medical Affairs. "At SK Life Science we are continually conducting research that will help healthcare professionals and equip them with the information they need to care for patients living with the challenges of epilepsy. We continue to do this via ongoing research, relevant post-hoc analyses, and the publication of real-world data on the use of cenobamate in the U.S. and globally."

Abstracts are available online on the AAN meeting website here and on site at booth #1262. The schedule of oral and poster presentations is detailed below.

Oral Presentations

Title: Comparative Effectiveness of Cenobamate in Reducing Hospitalizations in Patients with Focal-Onset Seizures: A Retrospective Claims-Based Analysis (Urban et al) Session: S29: Epilepsy Diagnostics and Therapeutics Date: Wednesday, April 17 Time: 1:24 PM

Title: Relative Bioavailability of Cenobamate 200 mg Administered as a Crushed Tablet, Either Orally or via Nasogastric Tube, vs an Intact 200-mg Cenobamate Tablet (Vashi et al) Session: S29: Epilepsy Diagnostics and Therapeutics Date: Wednesday, April 17 Time: 1:36 PM

Poster Presentations

Title: Effectiveness Of Cenobamate in Pediatric Patients with Lennox-Gastaut Syndrome: A Retrospective Claims-based Analysis (Keough et al) Session: P1: Epilepsy/Clinical Neurophysiology (EEG): Pediatric Epilepsy 1 Date: Sunday, April 14 Time: 8:00 9:00 AM

Title: Effectiveness Of Cenobamate in Pediatric Patients with Intractable Focal Seizures: A Retrospective Claims-based Analysis (Labiner et al) Session: P2: Epilepsy/Clinical Neurophysiology (EEG): Pediatric Epilepsy 2 Date: Sunday, April 14 Time: 11:45 AM 12:45 PM

Title: Increased Incidence of Comorbidities in Patients with Uncontrolled Epilepsy (Faught et al) Session: P4: Epilepsy/Clinical Neurophysiology (EEG): Epilepsy Co-morbidities and Special Populations Date: Monday, April 15 Time: 11:45 AM 12:45 PM

Title: Effectiveness Of Cenobamate in Postsurgical Patients: A Retrospective Claims-based Analysis (Pellinen et al) Session: P8: Epilepsy/Clinical Neurophysiology (EEG): Anti-seizure Medications: Clinical Trials and Outcomes Date: Tuesday: April 16 Time: 5:30 6:30 PM

Title: Cenobamate Use as Monotherapy: A Retrospective Claims-based Analysis (Becker et al) Session: P8: Epilepsy/Clinical Neurophysiology (EEG): Anti-seizure Medications: Clinical Trials and Outcomes Date: Tuesday, April 16 Time: 5:30 6:30 PM

Title: Dose Reduction Timing for Concomitant Antiseizure Medications: Post-hoc Analysis of a Phase 3, Open-label Study Of Cenobamate For Treatment Of Uncontrolled Focal Seizures (Ferrari et al) Session: P8: Epilepsy/Clinical Neurophysiology (EEG): Anti-seizure Medications: Clinical Trials and Outcomes Date: Tuesday, April 16 Time: 5:30 6:30 PM

AboutXCOPRI (cenobamatetablets) CV Cenobamateis an antiseizure medication (ASM) discovered and developed by SK Biopharmaceuticals and SK Life Science. While theprecise mechanism by whichcenobamateexerts its therapeutic effect is unknown, it is believed toreduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. It is also a positive allosteric modulator of the -aminobutyric acid (GABA A ) ion channel.

Cenobamateis approved in the United States for the treatment ofpartial-onset seizures inadults andis available under the brand name XCOPRI (cenobamatetablets) CV.Cenobamatecan be combined with other ASMs or used alone.The recommended initial dosage ofcenobamateis 12.5 mg once-daily, with titration every two weeks; it is available in six tablet strengths for once-daily dosing: 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg.

Cenobamateis also approved in the European Union and the United Kingdomfor the adjunctive treatment of focal-onset (partial-onset) seizures with or without secondary generalization in adult patients with seizuresthathave not been adequately controlled despite a history of treatment with at least two anti-epileptic medicinalproductsand is marketed by Angelini Pharma under the brand nameONTOZRY .

Additionally,cenobamateis in clinical development in Asia . Ono Pharmaceutical and Ignis Therapeutics have the rights to develop and commercializecenobamatein Japan and in the Greater China region, respectively.SK Biopharmaceuticals has recently entered into an exclusive licensing agreement with Endo for cenobamate in Canada .

IMPORTANT SAFETY INFORMATION AND INDICATION FOR XCOPRI (cenobamate tablets) CV

DO NOT TAKE XCOPRI IF YOU:

XCOPRI CAN CAUSE SERIOUS SIDE EFFECTS, INCLUDING:

Allergic reactions: XCOPRI can cause serious skin rash or other serious allergic reactions which may affect organs and other parts of your body like the liver or blood cells. You may or may not have a rash with these types of reactions. Call your healthcare provider right away and go to the nearest emergency room if you have any of the following: swelling of your face, eyes, lips, or tongue, trouble swallowing or breathing, a skin rash, hives, fever, swollen glands, or sore throat that does not go away or comes and goes, painful sores in the mouth or around your eyes, yellowing of your skin or eyes, unusual bruising or bleeding, severe fatigue or weakness, severe muscle pain, frequent infections, or infections that do not go away. Take XCOPRI exactly as your healthcare provider tells you to take it. It is very important to increase your dose of XCOPRI slowly, as instructed by your healthcare provider.

QT shortening: XCOPRI may cause problems with the electrical system of the heart (QT shortening). Call your healthcare provider if you have symptoms of QT shortening including fast heartbeat (heart palpitations) that last a long time or fainting.

Suicidal behavior and ideation: Antiepileptic drugs, including XCOPRI, may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call your health care provider right away if you have any of the following symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes in behavior or mood.

Nervous system problems: XCOPRI may cause problems that affect your nervous system. Symptoms of nervous system problems include: dizziness, trouble walking or with coordination, feeling sleepy and tired, trouble concentrating, remembering, and thinking clearly, and vision problems. Do not drive, operate heavy machinery, or do other dangerous activities until you know how XCOPRI affects you .

Do not drink alcohol or take other medicines that can make you sleepy or dizzy while taking XCOPRI without first talking to your healthcare provider.

DISCONTINUATION:

Do not stop taking XCOPRI without first talking to your healthcare provider. Stopping XCOPRI suddenly can cause serious problems. Stopping seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus).

DRUG INTERACTIONS:

XCOPRI may affect the way other medicines work, and other medicines may affect how XCOPRI works. Do not start or stop other medicines without talking to your healthcare provider. Tell healthcare providers about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

PREGNANCY AND LACTATION:

XCOPRI may cause your birth control medicine to be less effective. Talk to your health care provider about the best birth control method to use.

Talk to your health care provider if you are pregnant or plan to become pregnant. It is not known if XCOPRI will harm your unborn baby. Tell your healthcare provider right away if you become pregnant while taking XCOPRI. You and your healthcare provider will decide if you should take XCOPRI while you are pregnant. If you become pregnant while taking XCOPRI, talk to your healthcare provider about registering with the North American Antiepileptic Drug (NAAED) Pregnancy Registry. The purpose of this registry is to collect information about the safety of antiepileptic medicine during pregnancy. You can enroll in this registry by calling 1-888-233-2334 or go to http://www.aedpregnancyregistry.org .

Talk to your health care provider if you are breastfeeding or plan to breastfeed. It is not known if XCOPRI passes into breastmilk. Talk to your healthcare provider about the best way to feed your baby while taking XCOPRI.

COMMON SIDE EFFECTS:

The most common side effects in patients taking XCOPRI include dizziness, sleepiness, headache, double vision, and feeling tired.

These are not all the possible side effects of XCOPRI. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at http://www.fda.gov/medwatch .

DRUG ABUSE:

XCOPRI is a federally controlled substance (CV) because it can be abused or lead to dependence. Keep XCOPRI in a safe place to prevent misuse and abuse. Selling or giving away XCOPRI may harm others and is against the law.

INDICATION:

XCOPRI is a prescription medicine used to treat partial-onset seizures in adults 18 years of age and older. It is not known if XCOPRI is safe and effective in children under 18 years of age.

Please see additional patient information in the Medication Guide . This information does not take the place of talking with your healthcare provider about your condition or your treatment.

Please see full Prescribing Information .

About Epilepsy

Epilepsy is the fourth most common neurological disorder. Approximately 3.4 million people are living with epilepsy in the United States , with 150,000 new cases each year in the country. 1,2 Epilepsy is characterized by recurrent, unprovoked seizures. The seizures in epilepsy may be related to a brain injury or a family tendency, but often the cause is completely unknown. Having seizures and epilepsy can affect one's safety, relationships, work, driving, and much more. 3,4 People with epilepsy are at risk for accidents and other health complications, including falling, drowning, depression and sudden unexplained death in epilepsy (SUDEP). 3,4 Despite the availability of many antiepileptic therapies, almost 40 percent of people with epilepsy are not able to achieve seizure freedom, meaning they have epilepsy that remains uncontrolled. 5

About SK Biopharmaceuticals Co., Ltd. and SK Life Science, Inc.

SK Biopharmaceuticals and its U.S. subsidiary SK Life Science are pharmaceutical companies focused on the research, development, and commercialization of treatments for disorders of the central nervous system (CNS) and oncology. In 2017, SK Biopharmaceuticals established a research center to begin its expansion into oncology through research and development efforts. The companies have a pipeline of eight compounds in development in both CNS disorders and oncology. Additionally, SK Biopharmaceuticals is focused on the discovery of new treatments in oncology. For more information, visit SK Biopharmaceuticals' website at http://www.skbp.com/eng and SK Life Science's website at http://www.SKLifeScienceInc.com .

Both SK Biopharmaceuticals and SK Life Science are part of SK Group, one of the largest conglomerates in Korea. SK Inc., the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Inc. is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses.

References

View original content to download multimedia: https://www.prnewswire.com/news-releases/sk-life-science-announces-data-presentations-for-xcopri-cenobamate-tablets-cv-at-the-2024-american-academy-of-neurology-annual-meeting-302110843.html

SOURCE SK Life Science, Inc.

Read more here:
SK Life Science Announces Data Presentations for XCOPRI (cenobamate tablets) CV at the 2024 American Academy ... - InvestorsObserver

Recommendation and review posted by G. Smith


Page 11234..1020..»